22 January 2015

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces the following increase in the non-beneficial ownership of the ordinary shares in the Company held by James Barder, the Company's Chief Executive.

Futura today received notification that Robin A. Lamb, a significant shareholder in the Company, has acquired 500,000 ordinary shares in Futura for a trust of which Mr Barder is a trustee. The shares were acquired by the trust following the sale by Mr Lamb of 500,000 ordinary shares in Futura. The cash proceeds of the sale were settled into the trust, which then acquired 500,000 ordinary shares in Futura.

As a result, Mr Barder's revised aggregate beneficial and non-beneficial holding in Futura is 1,458,830 ordinary shares, representing 1.47% per cent of the Company's issued share capital.


For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000


Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.